- Δεν υπάρχουν δεδομένα
Ελληνικά
- English
- 简体中文
- 繁体中文
- Français
- Русский
- Italiano
- 日本語
- 한국어
- Português
- Deutsch
- Español
- Türkçe
- Ελληνικά
- Nederlands
- Tiếng Việt
- Polski
Meltio is an expert in the field of cost-effective linear laser metal deposition additive manufacturing technology (directed energy deposition, DED) and has launched the new Meltio Robot Cell, a turnkey metal additive manufacturing solution equipped with industrial robotic arms and the recently launched slicing software Meltio Space.The new hardware aligns with the vision of this Spanish company t...
A team of computer and electrical engineers at UC Santa Barbara, in collaboration with several colleagues at Caltech and another colleague at Anello Photonics, has developed a first-of-its-kind chip that can carry both laser and photonic waveguides. In a paper published in the journal Nature, the team describes how they made the chip and how it worked during testing.With the advent of integrated c...
Laser solder paste is a new type of high-tech laser soldering material that is widely used. Laser solder paste achieves high-precision control of circuit board soldering through laser heating in the electronic manufacturing process. This article will provide a detailed introduction to the working principle of laser solder paste and its applications in fields such as electronic manufacturing and au...
Longview Fusion Energy Systems and Fluor have taken another step towards commercialization of laser fusion power plants.According to the memorandum of understanding signed by the two companies, Fulu will design the factory for Longview Fusion Energy Systems. The two companies collaborated and signed a memorandum of understanding in 2023 to leverage Fulu's experience in developing and constructing ...
On July 3rd local time, Swiss ophthalmic care giant Alcon announced the acquisition of Israeli medical technology company Belkin Vision and its laser equipment assets for treating glaucoma.The transaction includes a prepayment of $81 million, of which approximately $65 million is in cash. In addition, if Alcon can establish this technology as the preferred first-line treatment option for clinical ...